The 11 most recent market catalysts affecting $CORT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
Corcept Therapeutics Says CHMP Recommends EU Approval Of Relacorilant With Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer; EC Decision Expected In Q4 2026
The CHMP recommendation for Relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer is a major positive catalyst for Corcept Therapeutics. This opens up the lucrativ…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165
Piper Sandler's reiteration of an 'Overweight' rating and a substantial increase in the price target for Corcept Therapeutics from $88 to $165 signals a strong vote of confidence f…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 92
Corcept Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates. Also, HC Wainwright raised its price target on the stock from $95 to $165.
This headline represents a major positive corporate catalyst for Corcept Therapeutics. The combination of beating earnings expectations, raising future sales guidance significantly…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165
HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a 'Buy' rating on Corcept Therapeutics (CORT) and raised the price target from $95 to $165. This substantial incre…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 95
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know
Corcept Therapeutics announced Q2 results that far exceeded analyst expectations, with revenue beating by 16.8% and EPS by an astounding 1,700%. This strong performance was attribu…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Wednesday's After-Market Session
This filing details the after-market performance of 12 healthcare stocks, with notable movers both up and down. The primary drivers for these movements appear to be company-specifi…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Corcept Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline indicates a strong positive corporate catalyst for Corcept Therapeutics. Better-than-expected financial results and an upward revision of future sales guidance signal…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Corcept Therapeutics Raises FY2026 Sales Guidance from $950.000M-$1.050B to $1.100B-$1.200B vs $1.008B Est
Corcept Therapeutics (CORT) announced a substantial increase in its FY2026 sales guidance, moving from an initial range of $950 million-$1.050 billion to a new range of $1.100 bill…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 92
Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate
Corcept Therapeutics reported Q2 EPS of $0.36, significantly beating the analyst consensus of $(0.00), and sales of $256.147 million, surpassing the $219.988 million estimate. This…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 75
Corcept Therapeutics shares are trading lower after Wolfe Research downgraded the stock from Peer Perform to Underperform and announced a $50 price target.
This headline represents a significant corporate catalyst for Corcept Therapeutics. Analyst downgrades, especially from a reputable firm like Wolfe Research, can materially impact …
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 65
Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target
Wolfe Research analyst Kalpit Patel downgraded Corcept Therapeutics (CORT) from Peer Perform to Underperform and announced a $50 price target. This analyst downgrade signals a more…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.